Straits Times Index
3,322.08 -8.69 (-0.26%) S&P 500
5,357.63 +10.64 (+0.20%) Dow
38,847.32 +48.33 (+0.12%) Nasdaq
17,180.52 +47.39 (+0.28%) Bitcoin USD
69,895.19 +259.20 (+0.37%) CMC Crypto 200
1,450.56 +3.89 (+0.27%)
BIIB Jan 2026 305.000 call
| Previous close | 15.20 |
| Open | 15.00 |
| Bid | 14.00 |
| Ask | 23.80 |
| Strike | 305.00 |
| Expiry date | 2026-01-16 |
| Day's range | 15.00 - 15.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 7 |
ZacksBiogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance
FDA accepts Biogen's (BIIB) partner Eisai's sBLA for a maintenance intravenous dosing version of Alzheimer's drug Leqembi. The final FDA decision is expected on Jan 25, 2025.
GlobeNewswireFDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI®) intravenous (IV) maintenance dosing. A Prescription Drug Us
ZacksWhy Is CRISPR Therapeutics (CRSP) Up 12% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
